Amgen (AMGN) EBITDA Margin (2009 - 2026)
Amgen (AMGN) recorded quarterly EBITDA Margin of 30.94% in Q1 2026, up 12.21% quarter-over-quarter from 27.57% in Q4 2025, and up 1648.0% on a YoY basis from 1.77% in Q1 2025.
Amgen (AMGN) EBITDA Margin (2009 - 2026) Analysis & Trends
Amgen's EBITDA Margin history runs 18 years deep, the most recent figure standing at 30.94% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 1648.0% year-over-year to 30.94%; the TTM figure through Mar 2026 stood at 28.39% (up 658.0% YoY), while the FY2025 annual figure was 24.71%, up 299.0% from the prior year.
- EBITDA Margin was 30.94% for Q1 2026 at Amgen, up from 27.57% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 485.84% in Q4 2022 to a low of 13.31% in Q1 2024.
- Historically, EBITDA Margin has averaged 54.56% across 5 years, with a median of 28.94% in 2025.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin surged 45218 bps in 2022, then plunged 47033 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 485.84% in 2022, then plunged by 97 bps to 15.51% in 2023, then surged by 64 bps to 25.43% in 2024, then grew by 8 bps to 27.57% in 2025, then climbed by 12 bps to 30.94% in 2026.
- The last three EBITDA Margin figures came in at 30.94% (Q1 2026), 27.57% (Q4 2025), and 26.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 24.65% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.94% |
| Dec 31, 2025 | 27.57% |
| Sep 30, 2025 | 26.43% |
| Jun 30, 2025 | 28.94% |
| Mar 31, 2025 | 14.46% |
| Dec 31, 2024 | 25.43% |
| Sep 30, 2024 | 24.07% |
| Jun 30, 2024 | 22.76% |
| Mar 31, 2024 | 13.31% |
| Dec 31, 2023 | 15.51% |
| Sep 30, 2023 | 29.28% |
| Jun 30, 2023 | 38.42% |
| Mar 31, 2023 | 31.47% |
| Dec 31, 2022 | 485.84% |
| Sep 30, 2022 | 39.99% |
| Jun 30, 2022 | 33.00% |
| Mar 31, 2022 | 40.08% |
| Dec 31, 2021 | 33.65% |
| Sep 30, 2021 | 35.46% |
| Jun 30, 2021 | 12.69% |